Skip to main content

Table 1 Demographic and clinical features of the patients studied

From: Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis

  APS SLE
  (n = 18) (n = 10)
Females/Males 15/3 9/1
Age in years   
   Mean (range) 38.4 (28–68) 36.9 (18–59)
Disease duration in months   
   Mean (range) 121 (1–322) 119 (12–300)
Vascular thrombosis   
   Venous thrombosis (percentage) 14/18 (77.7) 0
   Arterial thrombosis (percentage) 8/18 (44.4) 0
   Recurrent thrombosis (percentage) 4/14 (28.5) 0
Pregnancy morbidity   
   Normal foetus deaths (percentage) 0 0
   Premature births (percentage) 1/18 (5.5) 0
   Spontaneous abortions (percentage) 9/18 (50) 0
Serological features   
   aCL IgG (percentage) 18/18 (100) 10/10 (100)
   aCL IgM (percentage) 11/18 (61) 5/10 (50)
   Anti-β2-GPI IgG 18/18 (100) 10/10 (100)
   Anti-β2-GPI IgM ND ND
   Lupus anticoagulant activity (percentage)a 15/18 (83.3) 5/10 (50)
  1. aLupus anticoagulant activity was deduced from recent clinical records. aCL, anticardiolipin antibody; APS, antiphospholipid syndrome; β2-GPI, beta2-glycoprotein I; IgG, immunoglobulin G; IgM, immunoglobulin M; ND, not done; SLE, systemic lupus erythematosus.